Literature DB >> 2586614

Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins.

M L Brown1, A Inazu, C B Hesler, L B Agellon, C Mann, M E Whitlock, Y L Marcel, R W Milne, J Koizumi, H Mabuchi.   

Abstract

Plasma high density lipoproteins (HDL) are a negative risk factor for atherosclerosis. Increased HDL is sometimes clustered in families, but a genetic basis has never been clearly documented. The plasma cholesteryl ester transfer protein (CETP) catalyses the transfer of cholesteryl ester from HDL to other lipoproteins and therefore might influence HDL levels. Using monoclonal antibodies, we show that CETP is absent in two Japanese siblings who have markedly increased and enlarged HDL. Furthermore, they are homozygous for a point mutation in the 5'-splice donor site of intron 14 of the gene for CETP, a change that is incompatible with normal splicing of pre-messenger RNA. The results indicate that the family has an inherited deficiency of CETP due to a gene splicing defect, and illustrate the key role that CETP has in human HDL metabolism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2586614     DOI: 10.1038/342448a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  97 in total

1.  Biochemical characterization of cholesteryl ester transfer protein inhibitors.

Authors:  Mollie Ranalletta; Kathleen K Bierilo; Ying Chen; Denise Milot; Qing Chen; Elaine Tung; Caroline Houde; Nadine H Elowe; Margarita Garcia-Calvo; Gene Porter; Suzanne Eveland; Betsy Frantz-Wattley; Mike Kavana; George Addona; Peter Sinclair; Carl Sparrow; Edward A O'Neill; Ken S Koblan; Ayesha Sitlani; Brian Hubbard; Timothy S Fisher
Journal:  J Lipid Res       Date:  2010-05-10       Impact factor: 5.922

Review 2.  Plasma high density lipoproteins. Metabolism and relationship to atherogenesis.

Authors:  A R Tall
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

3.  Cardiovascular risk reduction via increasing HDL cholesterol: the promise of the dal-OUTCOMES Trial.

Authors:  Kyaw Soe; Anis Alam; Charles Philip; Edison Ruiz; Keshwar Ramkissoon; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

4.  Gene-based interaction analysis by incorporating external linkage disequilibrium information.

Authors:  Jing He; Kai Wang; Andrew C Edmondson; Daniel J Rader; Chun Li; Mingyao Li
Journal:  Eur J Hum Genet       Date:  2010-10-06       Impact factor: 4.246

Review 5.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 6.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 7.  Optimized negative-staining electron microscopy for lipoprotein studies.

Authors:  Lei Zhang; Huimin Tong; Mark Garewal; Gang Ren
Journal:  Biochim Biophys Acta       Date:  2012-09-29

Review 8.  Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.

Authors:  Davide Noto; Angelo B Cefalù; Maurizio R Averna
Journal:  Curr Atheroscler Rep       Date:  2014-06       Impact factor: 5.113

9.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol.

Authors:  A Inazu; X C Jiang; T Haraki; K Yagi; N Kamon; J Koizumi; H Mabuchi; R Takeda; K Takata; Y Moriyama
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  Bone marrow-derived HL mitigates bone marrow-derived CETP-mediated decreases in HDL in mice globally deficient in HL and the LDLr.

Authors:  Neil J Hime; Audrey S Black; David J Bonnet; Linda K Curtiss
Journal:  J Lipid Res       Date:  2014-05-12       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.